p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation
Terzian, Tamara, Torchia, Enrique C., Dai, Daisy, Robinson, Steven E., Murao, Kazutoshi, Stiegmann, Regan A., Gonzalez, Victoria, Boyle, Glen M., Powell, Marianne B., Pollock, Pamela M., Lozano, Guillermina, Robinson, William A., Roop, Dennis R., Box, Neil F., ,, & , (2010) p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell and Melanoma Research, 23(6), pp. 781-794.
p53 is the central member of a critical tumor suppressor pathway in virtually all tumor types, where it is silenced mainly by missense mutations. In melanoma, p53 predominantly remains wild type, thus its role has been neglected. To study the effect of p53 on melanocyte function and melanomagenesis, we crossed the 'high-p53'Mdm4+/- mouse to the well-established TP-ras0/+ murine melanoma progression model. After treatment with the carcinogen dimethylbenzanthracene (DMBA), TP-ras0/+ mice on the Mdm4+/- background developed fewer tumors with a delay in the age of onset of melanomas compared to TP-ras0/+ mice. Furthermore, we observed a dramatic decrease in tumor growth, lack of metastasis with increased survival of TP-ras0/+: Mdm4+/- mice. Thus, p53 effectively prevented the conversion of small benign tumors to malignant and metastatic melanoma. p53 activation in cultured primary melanocyte and melanoma cell lines using Nutlin-3, a specific Mdm2 antagonist, supported these findings. Moreover, global gene expression and network analysis of Nutlin-3-treated primary human melanocytes indicated that cell cycle regulation through the p21WAF1/CIP1 signaling network may be the key anti-melanomagenic activity of p53.
Citation countsare sourced monthly fromand citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||Animals, Cell Aging/drug effects, Cell Cycle/radiation effects, Cell Line, Tumor, Cell Proliferation/drug effects, Cell Survival/drug effects, Clone Cells, Disease Models, Animal, Disease Progression, Humans, Imidazoles/pharmacology, Melanocytes/drug effects/metabolism/pathology, Melanoma/metabolism/ pathology, Mice, Mice, Inbred C57BL, Nevus/metabolism/ pathology, Pigmentation/drug effects, Piperazines/pharmacology, Proto-Oncogene Proteins/metabolism, Skin Neoplasms/metabolism/ pathology, Staining and Labeling, Survival Analysis, Transcription, Genetic/drug effects, Tumor Suppressor Protein p53/genetics/ metabolism, Ubiquitin-Protein Ligases/metabolism|
|Subjects:||Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Cancer Genetics (111203)|
|Divisions:||Past > Schools > Cell & Molecular Biosciences|
Past > QUT Faculties & Divisions > Faculty of Science and Technology
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2010 John Wiley & Sons|
|Deposited On:||12 Sep 2011 09:28|
|Last Modified:||12 Sep 2011 09:28|
Repository Staff Only: item control page